To confirm that NR2F1 confers a survival benefit to melanoma cells in the presence of BRAFi + MEKi, we inducibly expressed either tdTomato-NR2F1-WT or a dominant-negative form of NR2F1, GFP-NR2F1-C141S, in 1205Lu-TR and WM793TR melanoma cells, which express the Tet repressor (TetR). Here, NR2F1 is linked to melanoma.